Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals
Background and Aim Early hepatocellular carcinoma (HCC) recurrence is common, even after achieving hepatitis C virus (HCV) cure. This study was carried out to assess the long‐term trends and predictors of recurrence after HCV cure by direct‐acting antivirals (DAAs). Methods This retrospective, multi...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2022-01, Vol.37 (1), p.190-199 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 199 |
|---|---|
| container_issue | 1 |
| container_start_page | 190 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 37 |
| creator | Ogawa, Eiichi Nakamuta, Makoto Furusyo, Norihiro Kajiwara, Eiji Dohmen, Kazufumi Kawano, Akira Ooho, Aritsune Azuma, Koichi Takahashi, Kazuhiro Satoh, Takeaki Koyanagi, Toshimasa Yamashita, Nobuyuki Ichiki, Yasunori Yamashita, Naoki Kuniyoshi, Masami Yanagita, Kimihiko Amagase, Hiromasa Morita, Chie Sugimoto, Rie Kato, Masaki Shimoda, Shinji Nomura, Hideyuki Hayashi, Jun |
| description | Background and Aim
Early hepatocellular carcinoma (HCC) recurrence is common, even after achieving hepatitis C virus (HCV) cure. This study was carried out to assess the long‐term trends and predictors of recurrence after HCV cure by direct‐acting antivirals (DAAs).
Methods
This retrospective, multicenter cohort study enrolled 365 consecutive patients with chronic hepatitis C who required HCC treatment following sustained viral response (SVR) by DAA administration. Patients with HCC recurrence before SVR were excluded. Late HCC recurrence and its predictors beyond the post‐treatment early phase (24 weeks after SVR) were evaluated.
Results
The data of 326 patients were available for the final analysis. The median follow‐up duration from SVR determination was 2.7 years. Median age was 74, and 220 (67.5%) were 70 or over. The corresponding 5‐year cumulative HCC recurrence rates of previous curative and palliative treatment groups were 45.4% and 65.7%, respectively (log‐rank test: P 7 ng/mL at 12 weeks after DAA administration, time from HCC complete response (CR) to DAA initiation ( |
| doi_str_mv | 10.1111/jgh.15659 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291903</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2560060819</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4439-81fafdfb1c07b00480cb8fcebeabe4fe338ebcc111839651b3953dbcb9a33f893</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi0EokvhwAsgS1zgkNaOk6x9QUKr0oJW4gJny_aON14l9mI7rfbGI3DoE_IkeJtSARK-jCx_8_8z_hF6SckZLed8t-3PaNu14hFa0KYhFV023WO0IJy2lWBUnKBnKe0IIQ1Ztk_RCWvYsqE1X6DbdfDbn99_ZIgjVilBSiP4jIPFEcwUI3gDx1sPe5WDgWGYBhWxUdE4H0aFncflxZWmhG9c7rHpY_DOzB0uu4RXWNligK9dVAMuqoD1AW9cccjFW5ns_BYrn90dkZ6jJ7YUeHFfT9HXDxdfVlfV-vPlx9X7dWWahomKU6vsxmpqyFKX3TgxmlsDGpSGxgJjHLQx5Yc4E11LNRMt22ijhWLMcsFO0btZdz_pETam7FDs5T66UcWDDMrJv1-86-U2XEtRCyoIKwJv7gVi-DZBynJ06fhHykOYkqzbjpCuxHD0ev0PugtT9GU9WXc15V0tOl6otzNlYkgpgn0YhhJ5zFqWrOVd1oV99ef0D-TvcAtwPgM3boDD_5Xkp8urWfIX7766Vw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2621862968</pqid></control><display><type>article</type><title>Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ogawa, Eiichi ; Nakamuta, Makoto ; Furusyo, Norihiro ; Kajiwara, Eiji ; Dohmen, Kazufumi ; Kawano, Akira ; Ooho, Aritsune ; Azuma, Koichi ; Takahashi, Kazuhiro ; Satoh, Takeaki ; Koyanagi, Toshimasa ; Yamashita, Nobuyuki ; Ichiki, Yasunori ; Yamashita, Naoki ; Kuniyoshi, Masami ; Yanagita, Kimihiko ; Amagase, Hiromasa ; Morita, Chie ; Sugimoto, Rie ; Kato, Masaki ; Shimoda, Shinji ; Nomura, Hideyuki ; Hayashi, Jun</creator><creatorcontrib>Ogawa, Eiichi ; Nakamuta, Makoto ; Furusyo, Norihiro ; Kajiwara, Eiji ; Dohmen, Kazufumi ; Kawano, Akira ; Ooho, Aritsune ; Azuma, Koichi ; Takahashi, Kazuhiro ; Satoh, Takeaki ; Koyanagi, Toshimasa ; Yamashita, Nobuyuki ; Ichiki, Yasunori ; Yamashita, Naoki ; Kuniyoshi, Masami ; Yanagita, Kimihiko ; Amagase, Hiromasa ; Morita, Chie ; Sugimoto, Rie ; Kato, Masaki ; Shimoda, Shinji ; Nomura, Hideyuki ; Hayashi, Jun ; Kyushu University Liver Disease Study (KULDS) Group ; The Kyushu University Liver Disease Study (KULDS) Group</creatorcontrib><description>Background and Aim
Early hepatocellular carcinoma (HCC) recurrence is common, even after achieving hepatitis C virus (HCV) cure. This study was carried out to assess the long‐term trends and predictors of recurrence after HCV cure by direct‐acting antivirals (DAAs).
Methods
This retrospective, multicenter cohort study enrolled 365 consecutive patients with chronic hepatitis C who required HCC treatment following sustained viral response (SVR) by DAA administration. Patients with HCC recurrence before SVR were excluded. Late HCC recurrence and its predictors beyond the post‐treatment early phase (24 weeks after SVR) were evaluated.
Results
The data of 326 patients were available for the final analysis. The median follow‐up duration from SVR determination was 2.7 years. Median age was 74, and 220 (67.5%) were 70 or over. The corresponding 5‐year cumulative HCC recurrence rates of previous curative and palliative treatment groups were 45.4% and 65.7%, respectively (log‐rank test: P < 0.001). Cox regression multivariable analysis revealed that cirrhosis (hazard ratio [HR] 1.85, P = 0.021), the number of HCC nodules (≥ 2) (HR 1.52, P = 0.031), and previous palliative HCC treatment (HR 1.71, P = 0.012) were independent predictors of late recurrence, in addition to the predictors of early recurrence; AFP > 7 ng/mL at 12 weeks after DAA administration, time from HCC complete response (CR) to DAA initiation (< 1 year), and the number of HCC treatments necessary to achieve CR (≥ 2).
Conclusions
The evaluation of fibrosis and characteristics of the previous HCC would allow for better HCC recurrence stratification, which would be helpful for developing long‐term surveillance strategies.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.15659</identifier><identifier>PMID: 34374128</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Antiviral agents ; Antiviral Agents - therapeutic use ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - virology ; Cirrhosis ; direct‐acting antivirals ; Fibrosis ; Hepatitis C ; hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatocellular carcinoma ; Humans ; Interferon ; Liver cancer ; Liver cirrhosis ; Liver Neoplasms - pathology ; Liver Neoplasms - virology ; Original ‐ Hepatology (Clinical) ; Patients ; Recurrence ; Regular ; Retrospective Studies ; Sustained Virologic Response ; Treatment Outcome</subject><ispartof>Journal of gastroenterology and hepatology, 2022-01, Vol.37 (1), p.190-199</ispartof><rights>2021 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4439-81fafdfb1c07b00480cb8fcebeabe4fe338ebcc111839651b3953dbcb9a33f893</citedby><cites>FETCH-LOGICAL-c4439-81fafdfb1c07b00480cb8fcebeabe4fe338ebcc111839651b3953dbcb9a33f893</cites><orcidid>0000-0002-5082-3967</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.15659$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.15659$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34374128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogawa, Eiichi</creatorcontrib><creatorcontrib>Nakamuta, Makoto</creatorcontrib><creatorcontrib>Furusyo, Norihiro</creatorcontrib><creatorcontrib>Kajiwara, Eiji</creatorcontrib><creatorcontrib>Dohmen, Kazufumi</creatorcontrib><creatorcontrib>Kawano, Akira</creatorcontrib><creatorcontrib>Ooho, Aritsune</creatorcontrib><creatorcontrib>Azuma, Koichi</creatorcontrib><creatorcontrib>Takahashi, Kazuhiro</creatorcontrib><creatorcontrib>Satoh, Takeaki</creatorcontrib><creatorcontrib>Koyanagi, Toshimasa</creatorcontrib><creatorcontrib>Yamashita, Nobuyuki</creatorcontrib><creatorcontrib>Ichiki, Yasunori</creatorcontrib><creatorcontrib>Yamashita, Naoki</creatorcontrib><creatorcontrib>Kuniyoshi, Masami</creatorcontrib><creatorcontrib>Yanagita, Kimihiko</creatorcontrib><creatorcontrib>Amagase, Hiromasa</creatorcontrib><creatorcontrib>Morita, Chie</creatorcontrib><creatorcontrib>Sugimoto, Rie</creatorcontrib><creatorcontrib>Kato, Masaki</creatorcontrib><creatorcontrib>Shimoda, Shinji</creatorcontrib><creatorcontrib>Nomura, Hideyuki</creatorcontrib><creatorcontrib>Hayashi, Jun</creatorcontrib><creatorcontrib>Kyushu University Liver Disease Study (KULDS) Group</creatorcontrib><creatorcontrib>The Kyushu University Liver Disease Study (KULDS) Group</creatorcontrib><title>Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background and Aim
Early hepatocellular carcinoma (HCC) recurrence is common, even after achieving hepatitis C virus (HCV) cure. This study was carried out to assess the long‐term trends and predictors of recurrence after HCV cure by direct‐acting antivirals (DAAs).
Methods
This retrospective, multicenter cohort study enrolled 365 consecutive patients with chronic hepatitis C who required HCC treatment following sustained viral response (SVR) by DAA administration. Patients with HCC recurrence before SVR were excluded. Late HCC recurrence and its predictors beyond the post‐treatment early phase (24 weeks after SVR) were evaluated.
Results
The data of 326 patients were available for the final analysis. The median follow‐up duration from SVR determination was 2.7 years. Median age was 74, and 220 (67.5%) were 70 or over. The corresponding 5‐year cumulative HCC recurrence rates of previous curative and palliative treatment groups were 45.4% and 65.7%, respectively (log‐rank test: P < 0.001). Cox regression multivariable analysis revealed that cirrhosis (hazard ratio [HR] 1.85, P = 0.021), the number of HCC nodules (≥ 2) (HR 1.52, P = 0.031), and previous palliative HCC treatment (HR 1.71, P = 0.012) were independent predictors of late recurrence, in addition to the predictors of early recurrence; AFP > 7 ng/mL at 12 weeks after DAA administration, time from HCC complete response (CR) to DAA initiation (< 1 year), and the number of HCC treatments necessary to achieve CR (≥ 2).
Conclusions
The evaluation of fibrosis and characteristics of the previous HCC would allow for better HCC recurrence stratification, which would be helpful for developing long‐term surveillance strategies.</description><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>Cirrhosis</subject><subject>direct‐acting antivirals</subject><subject>Fibrosis</subject><subject>Hepatitis C</subject><subject>hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Interferon</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - virology</subject><subject>Original ‐ Hepatology (Clinical)</subject><subject>Patients</subject><subject>Recurrence</subject><subject>Regular</subject><subject>Retrospective Studies</subject><subject>Sustained Virologic Response</subject><subject>Treatment Outcome</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kcFu1DAQhi0EokvhwAsgS1zgkNaOk6x9QUKr0oJW4gJny_aON14l9mI7rfbGI3DoE_IkeJtSARK-jCx_8_8z_hF6SckZLed8t-3PaNu14hFa0KYhFV023WO0IJy2lWBUnKBnKe0IIQ1Ztk_RCWvYsqE1X6DbdfDbn99_ZIgjVilBSiP4jIPFEcwUI3gDx1sPe5WDgWGYBhWxUdE4H0aFncflxZWmhG9c7rHpY_DOzB0uu4RXWNligK9dVAMuqoD1AW9cccjFW5ns_BYrn90dkZ6jJ7YUeHFfT9HXDxdfVlfV-vPlx9X7dWWahomKU6vsxmpqyFKX3TgxmlsDGpSGxgJjHLQx5Yc4E11LNRMt22ijhWLMcsFO0btZdz_pETam7FDs5T66UcWDDMrJv1-86-U2XEtRCyoIKwJv7gVi-DZBynJ06fhHykOYkqzbjpCuxHD0ev0PugtT9GU9WXc15V0tOl6otzNlYkgpgn0YhhJ5zFqWrOVd1oV99ef0D-TvcAtwPgM3boDD_5Xkp8urWfIX7766Vw</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Ogawa, Eiichi</creator><creator>Nakamuta, Makoto</creator><creator>Furusyo, Norihiro</creator><creator>Kajiwara, Eiji</creator><creator>Dohmen, Kazufumi</creator><creator>Kawano, Akira</creator><creator>Ooho, Aritsune</creator><creator>Azuma, Koichi</creator><creator>Takahashi, Kazuhiro</creator><creator>Satoh, Takeaki</creator><creator>Koyanagi, Toshimasa</creator><creator>Yamashita, Nobuyuki</creator><creator>Ichiki, Yasunori</creator><creator>Yamashita, Naoki</creator><creator>Kuniyoshi, Masami</creator><creator>Yanagita, Kimihiko</creator><creator>Amagase, Hiromasa</creator><creator>Morita, Chie</creator><creator>Sugimoto, Rie</creator><creator>Kato, Masaki</creator><creator>Shimoda, Shinji</creator><creator>Nomura, Hideyuki</creator><creator>Hayashi, Jun</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5082-3967</orcidid></search><sort><creationdate>202201</creationdate><title>Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals</title><author>Ogawa, Eiichi ; Nakamuta, Makoto ; Furusyo, Norihiro ; Kajiwara, Eiji ; Dohmen, Kazufumi ; Kawano, Akira ; Ooho, Aritsune ; Azuma, Koichi ; Takahashi, Kazuhiro ; Satoh, Takeaki ; Koyanagi, Toshimasa ; Yamashita, Nobuyuki ; Ichiki, Yasunori ; Yamashita, Naoki ; Kuniyoshi, Masami ; Yanagita, Kimihiko ; Amagase, Hiromasa ; Morita, Chie ; Sugimoto, Rie ; Kato, Masaki ; Shimoda, Shinji ; Nomura, Hideyuki ; Hayashi, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4439-81fafdfb1c07b00480cb8fcebeabe4fe338ebcc111839651b3953dbcb9a33f893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>Cirrhosis</topic><topic>direct‐acting antivirals</topic><topic>Fibrosis</topic><topic>Hepatitis C</topic><topic>hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Interferon</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - virology</topic><topic>Original ‐ Hepatology (Clinical)</topic><topic>Patients</topic><topic>Recurrence</topic><topic>Regular</topic><topic>Retrospective Studies</topic><topic>Sustained Virologic Response</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogawa, Eiichi</creatorcontrib><creatorcontrib>Nakamuta, Makoto</creatorcontrib><creatorcontrib>Furusyo, Norihiro</creatorcontrib><creatorcontrib>Kajiwara, Eiji</creatorcontrib><creatorcontrib>Dohmen, Kazufumi</creatorcontrib><creatorcontrib>Kawano, Akira</creatorcontrib><creatorcontrib>Ooho, Aritsune</creatorcontrib><creatorcontrib>Azuma, Koichi</creatorcontrib><creatorcontrib>Takahashi, Kazuhiro</creatorcontrib><creatorcontrib>Satoh, Takeaki</creatorcontrib><creatorcontrib>Koyanagi, Toshimasa</creatorcontrib><creatorcontrib>Yamashita, Nobuyuki</creatorcontrib><creatorcontrib>Ichiki, Yasunori</creatorcontrib><creatorcontrib>Yamashita, Naoki</creatorcontrib><creatorcontrib>Kuniyoshi, Masami</creatorcontrib><creatorcontrib>Yanagita, Kimihiko</creatorcontrib><creatorcontrib>Amagase, Hiromasa</creatorcontrib><creatorcontrib>Morita, Chie</creatorcontrib><creatorcontrib>Sugimoto, Rie</creatorcontrib><creatorcontrib>Kato, Masaki</creatorcontrib><creatorcontrib>Shimoda, Shinji</creatorcontrib><creatorcontrib>Nomura, Hideyuki</creatorcontrib><creatorcontrib>Hayashi, Jun</creatorcontrib><creatorcontrib>Kyushu University Liver Disease Study (KULDS) Group</creatorcontrib><creatorcontrib>The Kyushu University Liver Disease Study (KULDS) Group</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogawa, Eiichi</au><au>Nakamuta, Makoto</au><au>Furusyo, Norihiro</au><au>Kajiwara, Eiji</au><au>Dohmen, Kazufumi</au><au>Kawano, Akira</au><au>Ooho, Aritsune</au><au>Azuma, Koichi</au><au>Takahashi, Kazuhiro</au><au>Satoh, Takeaki</au><au>Koyanagi, Toshimasa</au><au>Yamashita, Nobuyuki</au><au>Ichiki, Yasunori</au><au>Yamashita, Naoki</au><au>Kuniyoshi, Masami</au><au>Yanagita, Kimihiko</au><au>Amagase, Hiromasa</au><au>Morita, Chie</au><au>Sugimoto, Rie</au><au>Kato, Masaki</au><au>Shimoda, Shinji</au><au>Nomura, Hideyuki</au><au>Hayashi, Jun</au><aucorp>Kyushu University Liver Disease Study (KULDS) Group</aucorp><aucorp>The Kyushu University Liver Disease Study (KULDS) Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2022-01</date><risdate>2022</risdate><volume>37</volume><issue>1</issue><spage>190</spage><epage>199</epage><pages>190-199</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aim
Early hepatocellular carcinoma (HCC) recurrence is common, even after achieving hepatitis C virus (HCV) cure. This study was carried out to assess the long‐term trends and predictors of recurrence after HCV cure by direct‐acting antivirals (DAAs).
Methods
This retrospective, multicenter cohort study enrolled 365 consecutive patients with chronic hepatitis C who required HCC treatment following sustained viral response (SVR) by DAA administration. Patients with HCC recurrence before SVR were excluded. Late HCC recurrence and its predictors beyond the post‐treatment early phase (24 weeks after SVR) were evaluated.
Results
The data of 326 patients were available for the final analysis. The median follow‐up duration from SVR determination was 2.7 years. Median age was 74, and 220 (67.5%) were 70 or over. The corresponding 5‐year cumulative HCC recurrence rates of previous curative and palliative treatment groups were 45.4% and 65.7%, respectively (log‐rank test: P < 0.001). Cox regression multivariable analysis revealed that cirrhosis (hazard ratio [HR] 1.85, P = 0.021), the number of HCC nodules (≥ 2) (HR 1.52, P = 0.031), and previous palliative HCC treatment (HR 1.71, P = 0.012) were independent predictors of late recurrence, in addition to the predictors of early recurrence; AFP > 7 ng/mL at 12 weeks after DAA administration, time from HCC complete response (CR) to DAA initiation (< 1 year), and the number of HCC treatments necessary to achieve CR (≥ 2).
Conclusions
The evaluation of fibrosis and characteristics of the previous HCC would allow for better HCC recurrence stratification, which would be helpful for developing long‐term surveillance strategies.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34374128</pmid><doi>10.1111/jgh.15659</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5082-3967</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2022-01, Vol.37 (1), p.190-199 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291903 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antiviral agents Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - virology Cirrhosis direct‐acting antivirals Fibrosis Hepatitis C hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatocellular carcinoma Humans Interferon Liver cancer Liver cirrhosis Liver Neoplasms - pathology Liver Neoplasms - virology Original ‐ Hepatology (Clinical) Patients Recurrence Regular Retrospective Studies Sustained Virologic Response Treatment Outcome |
| title | Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T01%3A33%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%E2%80%90term%20assessment%20of%20recurrence%20of%20hepatocellular%20carcinoma%20in%20patients%20with%20chronic%20hepatitis%20C%20after%20viral%20cure%20by%20direct%E2%80%90acting%20antivirals&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Ogawa,%20Eiichi&rft.aucorp=Kyushu%20University%20Liver%20Disease%20Study%20(KULDS)%20Group&rft.date=2022-01&rft.volume=37&rft.issue=1&rft.spage=190&rft.epage=199&rft.pages=190-199&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.15659&rft_dat=%3Cproquest_pubme%3E2560060819%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2621862968&rft_id=info:pmid/34374128&rfr_iscdi=true |